Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 16/20 | 0.43 |
| ▸ | JAK2 | O60674 | 12/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | WEE1 | P30291 | 1/20 | 0.38 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27378018 | 0.89 | ALOX5AP (0.38) | BTKJAK2PARP1CHEK1WEE1 | |
| SCHEMBL29326338 | 0.84 | BTK (0.42) | BTKJAK2ITGA4ITGB7CHEK1 | |
| SCHEMBL29326248 | 0.83 | KDM4E (0.45) | BTKJAK2ITGA4ITGB7NPEPPS | |
| SCHEMBL29326253 | 0.82 | NPEPPS (0.42) | ITGA4ITGB7NPEPPS | |
| SCHEMBL29326342 | 0.82 | NPEPPS (0.39) | ITGA4ITGB7CHEK1WEE1NPEPPS | |
| SCHEMBL29326170 | 0.80 | ERCC5 (0.42) | BTKJAK2ITGA4ITGB7NPEPPS | |
| SCHEMBL29326355 | 0.77 | PARP1 (0.42) | BTKPARP1ITGA4ITGB7 | |
| SCHEMBL29326760 | 0.75 | HSD17B10 (0.48) | CHEK1WEE1 | |
| SCHEMBL27192156 | 0.73 | FEN1 (0.39) | BTKJAK2CHEK1NPEPPS | |
| SCHEMBL27377720 | 0.72 | KDM4E (0.42) | BTKJAK2NPEPPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | BTK 2121/4885JAK2 1797/4885PARP1 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.